The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy

被引：0

作者：

Jimenez-Fonseca, Paula ^{[2
]}

Foy, Victoria ^{[3
]}

Raby, Sophie

Carmona-Bayonas, Alberto ^{[1
]}

Macia-Rivas, Lola ^{[4
]}

Arrazubi, Virginia ^{[5
]}

Cacho Lavin, Diego ^{[6
]}

Hernandez San Gil, Raquel ^{[7
]}

Custodio, Ana ^{[10
]}

Cano, Juana Maria ^{[9
]}

Fernandez Montes, Ana ^{[8
,11
]}

Mirallas, Oriol ^{[12
]}

Macias Declara, Ismael ^{[13
]}

Vidal Tocino, Rosario ^{[14
]}

Visa, Laura ^{[15
]}

Limon, Maria Luisa ^{[16
]}

Pimentel, Paola ^{[17
]}

Martinez Lago, Nieves ^{[18
]}

Sauri, Tamara ^{[19
]}

Martin Richard, Marta ^{[20
]}

Mangas, Monserrat ^{[21
]}

Gil Raga, Mireia

Calvo, Aitana ^{[22
]}

Reguera, Pablo ^{[23
]}

Granja, Monica ^{[24
,25
]}

Martin Carnicero, Alfonso ^{[26
]}

Hernandez Perez, Carolina ^{[27
]}

Cerda, Paula ^{[28
]}

Gomez Gonzalez, Lucia ^{[29
]}

Garcia Navalon, Francisco

Pacheco Barcia, Vilma ^{[30
]}

Gutierrez Abad, David ^{[31
]}

Ruiz Martin, Maribel ^{[32
]}

Weaver, Jamie ^{[33
]}

Mansoor, Wasat ^{[33
]}

Gallego, Javier ^{[34
]}

机构：

[1] Hosp Univ Morales Meseguer, Dept Hematol & Oncol Med, Calle Marques Velez S-N, Murcia 30800, Spain

[2] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain

[3] Christie Hosp, Dept Pathol, Manchester, Lancs, England

[4] Hosp Univ Cent Asturias, Pharm Dept, Oviedo, Spain

[5] Complejo Hosp Navarra, IdisNA Navarra Inst Hlth Res, Dept Pathol, Pamplona, Spain

[6] Hosp Univ Marques Valdecilla, Med Oncol Dept, IDIVAL, Santander, Spain

[7] Hosp Univ Canarias, Oncol Dept, Tenerife, Spain

[8] Hosp Univ La Paz, Med Oncol Dept, CIBERONC CB16-12-00398, Madrid, Spain

[9] Hosp Gen Univ Ciudad Real, Dept Nucl Med, Ciudad Real, Spain

[10] Complexo Hospitalario Univ Ourense, Dept Med Oncol, Orense, Spain

[11] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[12] Consorcio Hosp Univ Parc Tauli, Dept Med Oncol, Sabadell, Spain

[13] Complejo Asistencial Univ Salamanca, Dept Hematol, IBSAL, Salamanca, Spain

[14] Hosp Mar, Med Oncol Dept, Barcelona, Spain

[15] Hosp Univ Virgen Rocio, Med Oncol Dept, Seville, Spain

[16] St Lucia Univ Gen Hosp, Radiat Oncol Dept, Cartagena, Spain

[17] Complejo Hospitalario Univ A Coruna, Dept Med Oncol, La Coruna, Spain

[18] IDIBAPS, Hosp Clin, Dept Med Oncol, Barcelona, Spain

[19] Catalan Inst Oncol, Med Oncol Dept, Barcelona, Spain

[20] Hosp Galdakao Usansolo, Serv Angiol & Cirugia Vasc, Usansolo, Spain

[21] Consorcio Hosp Gen Univ Valencia, Med Oncol Dept, Valencia, Spain

[22] Hosp Univ Gregorio Maranon, Med Oncol Dept, Madrid, Spain

[23] Hosp Univ Ramon & Cajal, Med Oncol Dept, Madrid, Spain

[24] Hosp Univ Clin San Carlos, Med Oncol Dept, Madrid, Spain

[25] Hosp San Pedro, Med Oncol, Logrono, Spain

[26] Hosp Univ Nuestra Senora Candelaria, Med Oncol Dept, Santa Cruz De Tenerife, Spain

[27] Hosp Univ St Creu i St Pau, Dept Immunol, Barcelona, Spain

[28] Hosp Gen Univ Alicante, Dept Med Oncol, Alicante, Spain

[29] Hosp Univ Son Llatzer, Internal Med Dept, Palma De Mallorca, Spain

[30] Hosp Univ Torrejon, Med Oncol Dept, Madrid, Spain

[31] Hosp Univ Fuenlabrada, Dept Med Oncol, Madrid, Spain

[32] Rio Carr Hosp, Palencia, Spain

[33] Univ Manchester, Christie Hosp, Dept Med Oncol, Manchester, England

[34] Univ Elche, Dept Med Oncol, Gen Hosp, Elche 03203, Spain

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2023年 / 15卷

关键词：

gastric cancer; HER2-positive; nomogram; oesophageal cancer; survival; trastuzumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) and progression-free survival (PFS) in patients treated with trastuzumab.Methods: Patients with HER2-positive advanced gastro-oesophageal adenocarcinoma (AGA) from the Spanish Society of Medical Oncology (SEOM)-AGAMENON registry and treated first line with trastuzumab and chemotherapy between 2008 and 2021 were included. The model was externally validated in an independent series (The Christie NHS Foundation Trust, Manchester, UK).Results: In all, 737 patients were recruited (AGAMENON-SEOM, n = 654; Manchester, n = 83). Median PFS and OS in the training cohort were 7.76 [95% confidence interval (CI), 7.13-8.25] and 14.0 months (95% CI, 13.0-14.9), respectively. Six covariates were significantly associated with OS: neutrophil-to-lymphocyte ratio, Eastern Cooperative Oncology Group performance status, Lauren subtype, HER2 expression, histological grade and tumour burden. The AGAMENON-HER2 model demonstrated adequate calibration and fair discriminatory ability with a c-index for corrected PFS/OS of 0.606 (95% CI, 0.578-0.636) and 0.623 (95% CI, 0.594-0.655), respectively. In the validation cohort, the model is well calibrated, with a c-index of 0.650 and 0.683 for PFS and OS, respectively.Conclusion: The AGAMENON-HER2 prognostic tool stratifies HER2-positive AGA patients receiving trastuzumab and chemotherapy according to their estimated survival endpoints.

引用

页数：16

共 50 条

[31] Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer From Early Scientific Development to Foundation of Care
Brufsky, Adam
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (02): : 186 - 195
[32] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
Anthony F. Yu
Roy B. Mukku
Shivani Verma
Jennifer E. Liu
Kevin C. Oeffinger
Richard M. Steingart
Clifford A. Hudis
Chau T. Dang
Breast Cancer Research and Treatment, 2017, 166 : 241 - 247
[33] Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Sena Valcarcel
Javier Gallego
Paula Jimenez-Fonseca
Marc Diez
Eva Martínez de Castro
Raquel Hernandez
Virginia Arrazubi
Ana Custodio
Juana María Cano
Ana Fernández Montes
Ismael Macias
Laura Visa
Aitana Calvo
Rosario Vidal Tocino
Nieves Martínez Lago
María Luisa Limón
Mónica Granja
Mireia Gil
Paola Pimentel
Lola Macia-Rivas
Carolina Hernández Pérez
Montserrat Mangas
Alfonso Martín Carnicero
Paula Cerdà
Lucía Gomez Gonzalez
Francisco Garcia Navalon
Mª Dolores Mediano Rambla
Marta Martin Richard
Alberto Carmona-Bayonas
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 4077 - 4089
[34] A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy
Qian Li
Minzhi Lv
Huiqin Jiang
Yan Wang
Shan Yu
Wei Li
Yiyi Yu
Tianshu Liu
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 287 - 295
[35] An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer
Cardoso, Fatima
Canon, Jean-Luc
Amadori, Dino
Aldrighetti, Daniela
Machiels, Jean-Pascal
Bouko, Yasmina
Verkh, Lev
Usari, Tiziana
Kern, Kenneth A.
Giorgetti, Carla
Dirix, Luc
BREAST, 2012, 21 (06) : 716 - 723
[36] A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy
Li, Qian
Lv, Minzhi
Jiang, Huiqin
Wang, Yan
Yu, Shan
Li, Wei
Yu, Yiyi
Liu, Tianshu
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (01) : 287 - 295
[37] Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer
Yu, Anthony F.
Mukku, Roy B.
Verma, Shivani
Liu, Jennifer E.
Oeffinger, Kevin C.
Steingart, Richard M.
Hudis, Clifford A.
Dang, Chau T.
BREAST CANCER RESEARCH AND TREATMENT, 2017, 166 (01) : 241 - 247
[38] Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer
Sakaguchi, Koichi
Nakatsukasa, Katsuhiko
Koyama, Hiroshi
Kato, Makoto
Sakuyama, Akira
Matsuda, Takayuki
Tsunoda, Nobuyuki
Fujiwara, Ikuya
Yamaguchi, Masahide
Tanaka, Hiroki
Onishi, Kazuyoshi
Onishi, Mie
Yoshino, Yuji
Kikuchi, Takashi
Taguchi, Tetsuya
ANTICANCER RESEARCH, 2018, 38 (07) : 4073 - 4081
[39] Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
Tomas Baldassarre
Peter Truesdell
Andrew W. Craig
Breast Cancer Research, 19
[40] The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
Takahashi, Masato
Ohtani, Shoichiro
Nagai, Shigenori E.
Takashima, Seiki
Yamaguchi, Miki
Tsuneizumi, Michiko
Komoike, Yoshifumi
Osako, Tomofumi
Ito, Yoshinori
Ikeda, Masahiko
Ishida, Kazushige
Nakayama, Takahiro
Takashima, Tsutomu
Asakawa, Takashi
Matsumoto, Sho
Shimizu, Daisuke
Masuda, Norikazu
BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (01) : 125 - 134

← 1 2 3 4 5 →